Inspection Record

TAILSTORM HEALTH INC — FDA 483 Findings

US FDAInspected 2026-08-28Published 2026-09-29 5 findingsLaboratory and QC controlsDeviation, CAPA, and investigationAseptic processing and sterility assuranceEquipment and facility

Inspectors Ronda R Loyd JonesThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assume that components and drug products conform to appropriate standards of identity, strength, quality and purity.

2Deviation, CAPA, and investigation

Written records are not always made of investigations into unexplained discrepancies.

3Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

4Equipment and facility

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.

5Aseptic processing and sterility assurance

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

About this record

Extracted automatically from the document US FDA published on 2026-09-29. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

TAILSTORM HEALTH INC findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.